| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 33,030 | 38,630 | 41,290 | 44,260 | 33,890 |
| Sales Growth | -14.50% | -6.44% | -6.71% | +30.60% | +29.50% |
| Net Income | -44,630 | -41,060 | -37,920 | -23,570 | -19,080 |
| Net Income Growth | -8.69% | -8.28% | -60.88% | -23.53% | -61.42% |
Maxcyte Inc (MXCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
MaxCyte Inc. is a provider of cell-engineering enabling technology and is responsible cell-based therapies. MaxCyte Inc. is headquartered in Gaithersburg, Maryland.
Fiscal Year End Date: 12/31